Kloxxado® Newsroom

Assets and information for media and press use.


Images & Assets for Media Use

Kloxxado® Device (left-facing)

Kloxxado® Device (right-facing)

Download Our Media Kit for More

  • This field is for validation purposes and should be left unchanged.

Full media kit includes:

  • Kloxxado® Logo Files
  • Product Images
  • Manufacturing Video
  • Package Insert
  • Quick Start Guide
  • Kloxxado® Launch Press Release
  • Public Health Fact Sheet
  • Opioid Overdose and Naloxone Infographic

US FDA Approves Kloxxado® (naloxone HCl) Nasal Spray 8 mg to Treat Opioid Overdose

Hikma Pharmaceuticals announced, on April 30, 2021, the US Food and Drug Administration (FDA) approval of Kloxxado® (naloxone HCl) Nasal Spray 8 mg, a new opioid overdose reversal medication.

young mixed race woman looking at a laptop

Frequently Asked Questions

Learn more about Kloxxado® by exploring common patient and caregiver questions.

Go to Top

Important Safety Information About KLOXXADO® (naloxone HCl) Nasal Spray 8 mg